secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001213900-24-105782
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara TARA-002 shows 72% CR at 6 months in NMIBC Phase 2; 100% in BCG-unresponsive
--------------------------------------------------------------------------------

- 72% (13/18) landmark complete response rate at 6 months across BCG exposures; 70% (14/20) at any time.
- In BCG-unresponsive pivotal cohort: 100% (4/4) CR at 6 months; 80% (4/5) at any time.
- Favorable safety: no Grade 2+ treatment-related AEs; no discontinuations due to AEs; majority Grade 1 and transient.
- 100% (9/9) maintained CR from 3 to 6 months; 80% (4/5) re-induction salvage rate.
- Plans to report initial 12-month evaluable patient data in mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024105782/0001213900-24-105782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024105782/ea0223706-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-105782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer